• linkedin
  • Increase Font
  • Sharebar

    AUA IC/BPS guideline update highlights new data

    The AUA has updated its guideline on interstitial cystitis/bladder pain syndrome, with changes primarily focusing on aspects of treatment for a condition that affects three to eight million women and one to four million men in the United States.

    Updates reflect new data published in recent years, according to the chair of the guideline panel.

    RELATED: Genomic variation in IC/BPS based on bladder capacity

    The updates were announced in September to coincide with National Interstitial Cystitis Awareness Month, the AUA said in a press release. Among the amendments to the guideline:

    • In the “Second Line Treatment” section, a statement was updated to indicate that physical therapy techniques should be offered to a specific target population, namely patients who present with pelvic floor tenderness. Appropriate manual physical therapy techniques are defined as maneuvers that resolve pelvic, abdominal, and/or hip muscular trigger points; lengthen muscle contractures; and release painful scars and other connective tissue restrictions. In addition, the evidence level for this statement was upgraded to a Standard, Evidence Strength Grade A.
    • A “Fifth Line Treatment” statement about the use of intradetrusor botulinum toxin A (Botox) was moved to a “Fourth Line Treatment” statement. Botulinum toxin A “may be administered if other treatments have not provided adequate symptom control and quality of life or if the clinician and patient agree that symptoms require this approach,” according to the guideline. Intermittent self-catheterization may be necessary following this treatment, the guideline says.
      “Based on the literature review and consensus of the majority of guideline panel members, botulinum toxin A was moved from a fifth-line therapy recommendation to fourth line as an option to neurostimulation, which remains a fourth-line therapy,” guideline panel chair and Philip M. Hanno, MD, MPH, told Urology Times.
    • A statement about intravesical resiniferatoxin initially included as part of the “Treatments not to be offered” section was removed from the guideline. This agent is not available in the United States.

    Additionally, minor revisions to the guideline include the addition of new literature to the IC/BPS symptoms discussion, inclusion of new text to the Hunner’s lesions and cystoscopy discussion, and presentation of new evidence in the discussion of neurostimulation.


    Next: Dr. Hanno discusses updates

    More on Interstitial Cystitis

    Cannabinoid agonist may reduce cystitis severity, according to study

    Chemokines may predict response to neuromodulation

    Chronic pelvic pain syndrome patients prone to fibromyalgia, chronic fatigue


    Benjamin P. Saylor
    Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available